Fennec Pharmaceuticals Inc. (TSX:FRX)
Canada
· Delayed Price · Currency is CAD 9.21
0.00 (0.00%)
Mar 28, 2025, 3:37 PM EST
Fennec Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 26.63 | 13.27 | 23.77 | 21.1 | 30.34 | Upgrade
|
| Cash & Short-Term Investments | 26.63 | 13.27 | 23.77 | 21.1 | 30.34 | Upgrade
|
| Cash Growth | 100.72% | -44.19% | 12.67% | -30.46% | 122.30% | Upgrade
|
| Receivables | 12.88 | 8.81 | 1.55 | - | - | Upgrade
|
| Inventory | 1.06 | 2.16 | 0.58 | - | - | Upgrade
|
| Prepaid Expenses | 3.08 | 2.58 | 0.77 | 1.03 | 0.8 | Upgrade
|
| Other Current Assets | 0.47 | 0.04 | 0.06 | 0.25 | 0.28 | Upgrade
|
| Total Current Assets | 44.12 | 26.86 | 26.73 | 22.39 | 31.42 | Upgrade
|
| Long-Term Deferred Charges | - | - | 0.21 | 0.03 | - | Upgrade
|
| Other Long-Term Assets | 0.82 | 0.01 | - | - | - | Upgrade
|
| Total Assets | 44.95 | 26.86 | 26.94 | 22.41 | 31.42 | Upgrade
|
| Accounts Payable | 3.24 | 3.78 | 2.39 | 0.78 | 1.57 | Upgrade
|
| Accrued Expenses | 3.43 | 3.75 | 2.22 | 0.88 | 0.78 | Upgrade
|
| Current Portion of Leases | 0 | 0.02 | - | - | - | Upgrade
|
| Current Unearned Revenue | 0.25 | - | - | - | - | Upgrade
|
| Total Current Liabilities | 6.92 | 7.55 | 4.61 | 1.65 | 2.35 | Upgrade
|
| Long-Term Debt | 19.34 | 30.93 | 24.9 | 4.99 | - | Upgrade
|
| Long-Term Unearned Revenue | 24.56 | 0 | - | - | - | Upgrade
|
| Total Liabilities | 50.82 | 38.49 | 29.51 | 6.64 | 2.35 | Upgrade
|
| Common Stock | 145.61 | 144.31 | 142.59 | 140.8 | 140.73 | Upgrade
|
| Additional Paid-In Capital | 66.96 | 62.07 | 56.8 | 53.21 | 49.23 | Upgrade
|
| Retained Earnings | -219.68 | -219.25 | -203.2 | -179.49 | -162.14 | Upgrade
|
| Comprehensive Income & Other | 1.24 | 1.24 | 1.24 | 1.24 | 1.24 | Upgrade
|
| Shareholders' Equity | -5.87 | -11.62 | -2.57 | 15.77 | 29.07 | Upgrade
|
| Total Liabilities & Equity | 44.95 | 26.86 | 26.94 | 22.41 | 31.42 | Upgrade
|
| Total Debt | 19.34 | 30.95 | 24.9 | 4.99 | - | Upgrade
|
| Net Cash (Debt) | 7.29 | -17.68 | -1.13 | 16.11 | 30.34 | Upgrade
|
| Net Cash Growth | - | - | - | -46.90% | 122.30% | Upgrade
|
| Net Cash Per Share | 0.27 | -0.67 | -0.04 | 0.62 | 1.28 | Upgrade
|
| Filing Date Shares Outstanding | 27.59 | 27.1 | 26.41 | 26.01 | 26 | Upgrade
|
| Total Common Shares Outstanding | 27.53 | 27.03 | 26.36 | 26.01 | 26 | Upgrade
|
| Working Capital | 37.21 | 19.31 | 22.12 | 20.73 | 29.07 | Upgrade
|
| Book Value Per Share | -0.21 | -0.43 | -0.10 | 0.61 | 1.12 | Upgrade
|
| Tangible Book Value | -5.87 | -11.62 | -2.57 | 15.77 | 29.07 | Upgrade
|
| Tangible Book Value Per Share | -0.21 | -0.43 | -0.10 | 0.61 | 1.12 | Upgrade
|
Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.